目前市场上SGLT2抑制剂类产品还包括强生的Invokana(卡格列净,canagliflozin)和阿斯利康的Farxiga(达格列净,dapagliflozin)。它们通过增加尿液中葡萄糖的排泄来降低血糖,但是这类药物的高剂量与增加糖尿病酮症酸中毒(DKA)的风险有关。DKA会在体内形成一种称为酮的酸在体内积累,而且是1型糖尿病的并发症,可能危及生命。
参考来源:
[1] FDA Adcom Votes Against Lilly-Boehringer Ingelheim’s Jardiance in Type 1 Diabetes
[2] Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
[3] Eli Lilly, Boehringer hit FDA roadblock in quest to repurpose Jardiance for Type 1 diabetes
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。